Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yoshiki Negi
Observed names:
Negi, Yoshiki,
Y. Negi,
YOSHIKI NEGI
Institution:
Hyogo Medical University
Observed institution:
Hyogo Medical University
ORCID:
0009-0006-5059-4654
Observed ORCID:
0009-0006-5059-4654
OpenAlex ID:
A5068069330
Works
80
Awards
1
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
2023
·
Hayato Kawachi
, Tadaaki Yamada
, et al.
·
JAMA Network Open
·
35
PDF
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma
2017
·
Eriko Fujimoto
, Takashi Kijima
, et al.
·
Expert Review of Anticancer Therapy
·
27
Tumor‐associated macrophage‐derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma
2020
·
Daisuke Horio
, Toshiyuki Minami
, et al.
·
Cancer Science
·
25
PDF
EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest
2019
·
Hirotoshi Ishigaki
, Toshiyuki Minami
, et al.
·
Biochemical and Biophysical Research Communications
·
20
Adenosine Deaminase in Pleural Effusion and Its Relationship with Clinical Parameters in Patients with Malignant Pleural Mesothelioma
2020
·
Yasuhiro Nakajima
, Kozo Kuribayashi
, et al.
·
Cancer Investigation
·
17
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy
2024
·
Hayato Kawachi
, Tadaaki Yamada
, et al.
·
OncoImmunology
·
14
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
2023
·
Daisuke Hazama
, Kenji Nakahama
, et al.
·
JTO Clinical and Research Reports
·
14
PDF
Successful Treatment of Pulmonary Pleomorphic Carcinoma with Nivolumab: A Case Report
2018
·
Eriko Fujimoto
, Takashi Yokoi
, et al.
·
Case Reports in Oncology
·
13
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study
2024
·
Naoya Nishioka
, Hayato Kawachi
, et al.
·
Frontiers in Immunology
·
10
PDF
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study
2024
·
Naoya Nishioka
, Tae Hata
, et al.
·
Cancer Research and Treatment
·
9
PDF
Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
2023
·
Akio Tada
, Toshiyuki Minami
, et al.
·
Lung Cancer
·
9
PDF
Early-stage Clinical Characterization of Malignant Pleural Mesothelioma
2018
·
YOSHIKI NEGI
, KOZO KURIBAYASHI
, et al.
·
In Vivo
·
9
PDF
KEYNOTE ‐ A17 : First‐Line Pembrolizumab Plus Cisplatin–Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma
2025
·
Takashi Kijima
, Terufumi Kato
, et al.
·
Cancer Science
·
6
PDF
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan
2025
·
Shiho Goda
, Tadaaki Yamada
, et al.
·
Translational Lung Cancer Research
·
6
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%
2024
·
Shota Takei
, Hayato Kawachi
, et al.
·
Frontiers in Immunology
·
6
PDF
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
2025
·
Tae Hata
, Tadaaki Yamada
, et al.
·
Cancer Research Communications
·
5
PDF
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
2024
·
Yusuke Tachibana
, Kenji Morimoto
, et al.
·
Investigational New Drugs
·
5
Nivolumab treatment followed by atezolizumab induced encephalitis and neuropathy with antiganglioside antibodies
2021
·
Shohei Watanabe
, Kazuki Yoshizumi
, et al.
·
eNeurologicalSci
·
5
Utility of serum CYFRA 21-1 as a prognostic biomarker in ALK-positive non-small cell lung cancer treated with ALK-TKIs: a retrospective cohort study
2025
·
Ryo Sawada
, Tadaaki Yamada
, et al.
·
Translational Lung Cancer Research
·
4
Sarcomatoid malignant pleural mesothelioma associated with anti-Ma2-related paraneoplastic neurological syndrome: A case report
2023
·
Akio Tada
, Kozo Kuribayashi
, et al.
·
Current Problems in Cancer Case Reports
·
4
Successful Management of Steroid‐Refractory Immune‐Related Pneumonitis With Mycophenolate Mofetil: A Case Report
2025
·
Hiroaki Ota
, Daichi Fujimoto
, et al.
·
Respirology Case Reports
·
3
PDF
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)
2025
·
Masashi Ishihara
, Takahisa Kawamura
, et al.
·
Therapeutic Advances in Medical Oncology
·
3
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
2023
·
Kenji Morimoto
, Tadaaki Yamada
, et al.
·
Targeted Oncology
·
3
Efficacy and safety of nivolumab for malignant mesothelioma in the real world.
2020
·
Koji Mikami
, Takashi Yokoi
, et al.
·
Journal of Clinical Oncology
·
3
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression
2025
·
AOSA SASADA
, HAYATO KAWACHI
, et al.
·
Anticancer Research
·
2
Show more works
View as search
Works count:
80
Citation count:
265
H-index:
9
I10-index:
9
Year
Topic
Type